Microhealth

What we do?

We develop digital therapeutics to address unmet medical needs in hematology and oncology.

How it works?

First we build networks of doctors and patients designed to track, predict and prevent disease. Second, we validate the safety and efficacy of our interventions in pivotal clinical studies to obtain regulatory clearance (SaMD). Finally, we aim to commercialize our products as prescription digital therapeutics (DTx).

Where are we now?

Today, we are the standard in digital hematology:

* Our hemophilia network covers 33% of all patients and providers in the US.

* We bested 20+ competitors, including several Fortune 500 companies.

* Our clients include: Sanofi, Bayer, Novo Nordisk, Biogen, and Roche.

High-Level Overview

MicroHealth is a leading digital hematology platform focused on delivering digital therapeutics and health management tools for blood disorders such as hemophilia and sickle cell disease. It builds mobile applications and platforms that empower patients and healthcare providers to track, manage, and improve treatment adherence and outcomes. Serving patients, healthcare professionals, and pharmaceutical companies, MicroHealth addresses unmet medical needs by enabling remote care and real-world data collection to support research and regulatory validation. The company has gained significant traction, covering over 33% of hemophilia patients and providers in the U.S., and collaborates with major biopharma clients like Sanofi, Bayer, and Roche[1][2][4][7].

Origin Story

Founded in 2015 by Miguel Lara, a digital health entrepreneur with deep biopharma ties, and Marc Lara, an expert in digital health and predictive AI, MicroHealth emerged from a collaboration between a patient with severe hemophilia and a Columbia University medical researcher. This partnership highlighted the invisibility of patient voices in traditional healthcare, inspiring the creation of a platform to connect patients and providers beyond clinical settings for better outcomes. Early validation came from rapid adoption within the hemophilia community and support from incubators like Y Combinator and Plug and Play[1][2][4][6].

Core Differentiators

• Product Differentiators: MicroHealth offers comprehensive digital therapeutics designed specifically for hematology and oncology, including apps for infusion logging, bleed tracking, and a healthcare provider portal with tools like a vial calculator[4][8].
• Developer Experience: The platform emphasizes user engagement and long-term usability, guided by a "Hell Yeah or No" decision-making culture focused on patient benefit[6].
• Speed, Pricing, Ease of Use: Free access to patient apps on iOS and Android, combined with secure, encrypted data handling and regulatory compliance, facilitates broad adoption and trust[7][8].
• Community Ecosystem: MicroHealth has built a robust network covering a third of U.S. hemophilia patients and providers, integrating patient organizations, specialty pharmacies, and global advocacy groups to advance research and care[4][6][7].

Role in the Broader Tech Landscape

MicroHealth rides the growing trend of digital therapeutics and remote patient monitoring, particularly in specialized chronic disease management. The timing aligns with increasing demand for patient-centered care, real-world evidence in regulatory processes, and digital health integration in biopharma. Market forces such as rising healthcare costs, telehealth expansion, and data-driven personalized medicine favor MicroHealth’s model. By creating a scalable platform that connects patients, providers, and researchers, MicroHealth influences the hematology ecosystem and sets a precedent for digital health innovation in rare diseases[4][6].

Quick Take & Future Outlook

Looking ahead, MicroHealth is poised to expand its digital therapeutics portfolio, deepen partnerships with pharmaceutical companies, and pursue regulatory clearances to commercialize prescription digital therapeutics. Trends shaping its journey include advances in AI-driven predictive analytics, increasing regulatory acceptance of digital health tools, and growing patient demand for remote, personalized care. As it scales, MicroHealth’s influence may extend beyond hematology into broader chronic disease management, continuing to bridge gaps between patients, providers, and researchers while driving improved health outcomes and economic value[4][6].

This trajectory reflects MicroHealth’s foundational mission: to make the patient’s voice visible and actionable in healthcare, transforming blood disorder management through technology.